24.685 USD
-0.29 (-1.14%)
Overall APLS gets a fundamental rating of 5 out of 10. We evaluated APLS against 531 industry peers in the Biotechnology industry. Both the profitability and the financial health of APLS get a neutral evaluation. Nothing too spectacular is happening here. APLS is not overvalued while it is showing excellent growth. This is an interesting combination. This makes APLS very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year APLS was profitable.
In the past year APLS had a positive cash flow from operations.
APLS had negative earnings in each of the past 5 years.
APLS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.25%, APLS belongs to the top of the industry, outperforming 90.58% of the companies in the same industry.
APLS's Return On Equity of 11.21% is amongst the best of the industry. APLS outperforms 93.22% of its industry peers.
With an excellent Return On Invested Capital value of 8.15%, APLS belongs to the best of the industry, outperforming 93.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.25% | ||
| ROE | 11.21% | ||
| ROIC | 8.15% |
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of APLS (4.43%) is better than 89.45% of its industry peers.
APLS's Operating Margin of 7.91% is amongst the best of the industry. APLS outperforms 90.40% of its industry peers.
The Gross Margin of APLS (88.85%) is better than 90.58% of its industry peers.
In the last couple of years the Gross Margin of APLS has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.91% | ||
| PM (TTM) | 4.43% | ||
| GM | 88.85% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), APLS is destroying value.
Compared to 1 year ago, APLS has more shares outstanding
Compared to 5 years ago, APLS has more shares outstanding
APLS has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.99, we must say that APLS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.99, APLS is in the better half of the industry, outperforming 61.39% of the companies in the same industry.
The Debt to FCF ratio of APLS is 5.78, which is a neutral value as it means it would take APLS, 5.78 years of fcf income to pay off all of its debts.
APLS has a Debt to FCF ratio of 5.78. This is amongst the best in the industry. APLS outperforms 91.15% of its industry peers.
A Debt/Equity ratio of 0.90 indicates that APLS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.90, APLS is not doing good in the industry: 76.08% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 5.78 | ||
| Altman-Z | 0.99 |
ROIC/WACC0.95
WACC8.58%
2.3 Liquidity
APLS has a Current Ratio of 3.54. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of APLS (3.54) is comparable to the rest of the industry.
APLS has a Quick Ratio of 3.10. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
APLS has a worse Quick ratio (3.10) than 61.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 116.40% over the past year.
The Revenue has grown by 42.11% in the past year. This is a very strong growth!
Measured over the past years, APLS shows a very strong growth in Revenue. The Revenue has been growing by 127.23% on average per year.
EPS 1Y (TTM)116.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%463.04%
Revenue 1Y (TTM)42.11%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%132.98%
3.2 Future
APLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.97% yearly.
APLS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.78% yearly.
EPS Next Y118.29%
EPS Next 2Y10.76%
EPS Next 3Y25.01%
EPS Next 5Y26.97%
Revenue Next Year28.85%
Revenue Next 2Y6.33%
Revenue Next 3Y10.9%
Revenue Next 5Y13.78%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 79.63, which means the current valuation is very expensive for APLS.
Compared to the rest of the industry, the Price/Earnings ratio of APLS indicates a rather cheap valuation: APLS is cheaper than 89.83% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.76, APLS is valued quite expensively.
APLS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 79.63 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, APLS is valued cheaper than 91.53% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, APLS is valued cheaply inside the industry as 93.03% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 39.72 | ||
| EV/EBITDA | 38.18 |
4.3 Compensation for Growth
APLS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as APLS's earnings are expected to grow with 25.01% in the coming years.
PEG (NY)0.67
PEG (5Y)N/A
EPS Next 2Y10.76%
EPS Next 3Y25.01%
5. Dividend
5.1 Amount
APLS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:APLS (12/12/2025, 1:10:26 PM)
24.685
-0.29 (-1.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.54%
Inst Owner Change-5.86%
Ins Owners3.7%
Ins Owner Change-0.16%
Market Cap3.12B
Revenue(TTM)1.02B
Net Income(TTM)44.99M
Analysts77.86
Price Target36.24 (46.81%)
Short Float %15.34%
Short Ratio6.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.57%
Min EPS beat(2)31.03%
Max EPS beat(2)38.1%
EPS beat(4)3
Avg EPS beat(4)-1.49%
Min EPS beat(4)-101.36%
Max EPS beat(4)38.1%
EPS beat(8)5
Avg EPS beat(8)-4.2%
EPS beat(12)7
Avg EPS beat(12)-3.46%
EPS beat(16)7
Avg EPS beat(16)-4.53%
Revenue beat(2)1
Avg Revenue beat(2)1.69%
Min Revenue beat(2)-7.17%
Max Revenue beat(2)10.55%
Revenue beat(4)2
Avg Revenue beat(4)-1.99%
Min Revenue beat(4)-16.4%
Max Revenue beat(4)10.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.73%
Revenue beat(12)7
Avg Revenue beat(12)7.96%
Revenue beat(16)10
Avg Revenue beat(16)42.21%
PT rev (1m)-6.37%
PT rev (3m)-5.96%
EPS NQ rev (1m)-8.56%
EPS NQ rev (3m)-29.05%
EPS NY rev (1m)1186.5%
EPS NY rev (3m)133.58%
Revenue NQ rev (1m)-1.76%
Revenue NQ rev (3m)-5.96%
Revenue NY rev (1m)2.88%
Revenue NY rev (3m)6.98%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 79.63 | ||
| Fwd PE | N/A | ||
| P/S | 3.07 | ||
| P/FCF | 39.72 | ||
| P/OCF | 39.61 | ||
| P/B | 7.79 | ||
| P/tB | 7.79 | ||
| EV/EBITDA | 38.18 |
EPS(TTM)0.31
EY1.26%
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)0.62
FCFY2.52%
OCF(TTM)0.62
OCFY2.52%
SpS8.03
BVpS3.17
TBVpS3.17
PEG (NY)0.67
PEG (5Y)N/A
Graham Number4.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.25% | ||
| ROE | 11.21% | ||
| ROCE | 10.32% | ||
| ROIC | 8.15% | ||
| ROICexc | 21.17% | ||
| ROICexgc | 21.17% | ||
| OM | 7.91% | ||
| PM (TTM) | 4.43% | ||
| GM | 88.85% | ||
| FCFM | 7.74% |
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
F-Score7
Asset Turnover0.96
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 5.78 | ||
| Debt/EBITDA | 4.4 | ||
| Cap/Depr | 13.41% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 1.92 | ||
| Cash Conversion | 96.08% | ||
| Profit Quality | 174.81% | ||
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 0.99 |
F-Score7
WACC8.58%
ROIC/WACC0.95
Cap/Depr(3y)54.61%
Cap/Depr(5y)218.08%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%463.04%
EPS Next Y118.29%
EPS Next 2Y10.76%
EPS Next 3Y25.01%
EPS Next 5Y26.97%
Revenue 1Y (TTM)42.11%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%132.98%
Revenue Next Year28.85%
Revenue Next 2Y6.33%
Revenue Next 3Y10.9%
Revenue Next 5Y13.78%
EBIT growth 1Y136%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year148.49%
EBIT Next 3Y34.96%
EBIT Next 5Y33.37%
FCF growth 1Y112.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y112.37%
OCF growth 3YN/A
OCF growth 5YN/A
APELLIS PHARMACEUTICALS INC / APLS FAQ
Can you provide the ChartMill fundamental rating for APELLIS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to APLS.
Can you provide the valuation status for APELLIS PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 5 / 10 to APELLIS PHARMACEUTICALS INC (APLS). This can be considered as Fairly Valued.
What is the profitability of APLS stock?
APELLIS PHARMACEUTICALS INC (APLS) has a profitability rating of 5 / 10.
What are the PE and PB ratios of APELLIS PHARMACEUTICALS INC (APLS) stock?
The Price/Earnings (PE) ratio for APELLIS PHARMACEUTICALS INC (APLS) is 79.63 and the Price/Book (PB) ratio is 7.79.